Opportunities for and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era

Opportunities for and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era

The dynamic nature of infectious diseases introduces inherent challenges to the design of vaccine clinical trials, which consequently makes vaccine indirect treatment comparisons (ITCs) and meta-analyses (MAs) more challenging compared with regular pharmaceuticals. However, comparisons of efficacy a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Charlotte Graham, Erin Barker, Joe Moss, Emily Gregg, Rachael McCool, Nathalie Largeron, Mélanie Trichard, José Bartelt-Hofer, Maribel Tribaldos
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Journal of Market Access & Health Policy
Subjects:	indirect treatment comparison meta-analysis comparative effectiveness vaccine health technology assessment EU Regulation on Health Technology Assessment
Online Access:	https://www.mdpi.com/2001-6689/13/2/31
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Using indirect comparisons in pharmacoeconomic examination
by: Yu. E. Balykina, et al.
Published: (2015-03-01)

Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs
by: Francisco Javier Parrondo-García, et al.
Published: (2021-03-01)

INDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT
by: S. V. Goryajnov, et al.
Published: (2012-04-01)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
by: Krzysztof Lach, et al.
Published: (2017-01-01)

EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity?
by: Volker Schuster
Published: (2024-05-01)

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
by: Thomas Desmet, et al.
Published: (2024-03-01)

Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons
by: Nils Erik Gilhus, et al.
Published: (2025-05-01)

The Role of HTA for Essential Health Benefit Package Design in Low or Middle-Income Countries
by: Ole F. Norheim, et al.
Published: (2023-12-01)

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire
by: Lauren Van Haesendonck, et al.
Published: (2023-12-01)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
by: Clara Monleón, et al.
Published: (2022-12-01)

Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop
by: Ting Wang, et al.
Published: (2025-03-01)

Health technology assessment (HTA) and performance management (PM): a scoping review on the intersecting realms
by: Esther Oluwatosin Akinbobola, et al.
Published: (2025-07-01)

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison
by: Sonja Ständer, et al.
Published: (2025-07-01)

Cost of epilepsy in the Russian Federation
by: A. S. Romanov, et al.
Published: (2024-10-01)

The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy
by: Elaine Julian, et al.
Published: (2024-06-01)

Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR
by: Emanuele Arcà, et al.
Published: (2025-06-01)

THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT
by: V. I. Ignatyeva, et al.
Published: (2015-03-01)

COMPARATIVE CHARACTERISTICS OF THE EFFECTIVENESS OF DIRECT AND INDIRECT RESTORATIONS ON TEETH WITH DISCOLORATION
by: I.V. Zhyvotovskyi, et al.
Published: (2019-09-01)

Approaches to resolve practical challenges in the context of assessing the price of biosimilar products
by: A. H.-M. Valeeva, et al.
Published: (2025-01-01)

Institutionalizing Health Technology Assessment in Ghana: Enablers, Constraints, and Lessons
by: Augustina Koduah, et al.
Published: (2023-12-01)

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review
by: Bérengère Macabeo, et al.
Published: (2024-04-01)

THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01)

Approaches for Health Technology Assessment in Europe: Situational Analysis
by: Slaveyko Djambazov, et al.
Published: (2016-12-01)

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks
by: Suzy van Sanden, et al.
Published: (2025-06-01)

Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
by: Vipul Jairath, et al.
Published: (2025-02-01)

Radiofrequency or cryoablation or medical therapy for paroxysmal atrial fibrillation: An indirect comparison of effectiveness
by: Roberto Brunoro, et al.
Published: (2025-04-01)

HTA CORE MODEL
by: R. I. Yagudina, et al.
Published: (2015-03-01)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016-12-01)

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
by: Sarah Walsh, et al.
Published: (2025-07-01)

The economic evaluation of a vaccination against pertussis infection in children in Moscow
by: S. V. Svetlichnaya, et al.
Published: (2023-10-01)

Review of methods for assessing the cost-effectiveness of medical interventions
by: T. I. Busheva, et al.
Published: (2025-01-01)

The global landscape of country-level health technology assessment processes: A survey among 104 countries
by: Andrew J. Mirelman, et al.
Published: (2025-06-01)

Towards the Operationalization of Health Technology Sustainability Assessment and the Early Eco Design of the Internet of Medical Things
by: Ernesto Quisbert-Trujillo, et al.
Published: (2025-06-01)

Judicial claims for access to treatment in the private health insurance sector in Brazil
by: Daniel Wei Liang Wang, et al.

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data
by: Vera Damuzzo, et al.
Published: (2025-05-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

Review of the current approaches to the assessment of the drug innovative potential worldwide
by: N. Z. Musina, et al.
Published: (2017-11-01)

Digital assessments for children and adolescents with ADHD: a scoping review
by: Franceli L. Cibrian, et al.
Published: (2024-10-01)

The need to consider market access for pharmaceutical investment decisions: a primer
by: Sreeram V Ramagopalan, et al.
Published: (2025-04-01)

Corrigendum: Digital assessments for children and adolescents with ADHD: a scoping review
by: Franceli L. Cibrian, et al.
Published: (2024-11-01)